Lab-grown food pipe restores swallowing in piglets - without immunosuppression

Casey Mcintyre is two years old. He loves his dog Daisy. He has also spent roughly half his life in hospital. Casey was born missing 11 centimeters of his oesophagus - the muscular tube that moves food from the throat to the stomach - and the surgical options for closing a gap that large are limited, invasive, and carry lifelong complications.

His story is not unusual. About 180 babies are born with oesophageal atresia in the UK each year, and roughly 10 percent of them have the long-gap form, where the upper and lower segments of the food pipe are too far apart to reconnect. These children cannot eat. They rely on feeding tubes placed directly into their stomachs while surgical teams figure out what to do next. The current options - repositioning the stomach or intestine to bridge the gap - are major operations with significant risks, including breathing problems, gastrointestinal complications, and an unknown long-term cancer risk.

A study published in Nature Biotechnology now describes a different path: a lab-grown oesophagus built from a donor scaffold and the recipient's own cells, capable of restoring swallowing and growing with the animal.

Stripping a donor organ down to its scaffold

The approach, developed by researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL), starts with a donor pig's oesophagus. Through a process called decellularisation, all cellular material is removed from the donor tissue, leaving behind only the structural framework - the extracellular matrix that gives the organ its shape, its mechanical properties, and its biological cues for guiding new cell growth.

This is not a new idea in tissue engineering. What makes this study different is the completeness of what followed. The team took muscle cells from a small biopsy of the recipient pig, multiplied them in the lab, and injected them into the scaffold. The seeded graft then spent a week in a bioreactor - a container that pumps growth fluids through the tissue, giving the cells time to settle, spread, and adapt to their new environment. The entire process, from biopsy to implant-ready graft, takes about two months.

That timeline matters. Two months is compatible with the current standard of care for babies with long-gap oesophageal atresia, who are already waiting with feeding tubes while their medical teams plan treatment.

Eight animals, six months, functional swallowing

The study implanted engineered oesophageal grafts in eight pigs. All eight survived the critical first 30 days after transplant. By six months, the grafts had developed functional muscle, nerves, and blood vessels. The transplanted oesophagus could contract and move food - the coordinated muscular action known as peristalsis that makes swallowing possible. The animals ate normally and grew at healthy rates.

None required immunosuppression. Because the graft was built using the recipient's own cells on a decellularized scaffold, the immune system treated it as self.

The team used spatial transcriptomics - a technique that maps gene activity to specific locations within a tissue - to confirm that the genes active in the engineered oesophagus matched what would be expected in native tissue. The graft progressively regenerated normal oesophageal structures: a barrier layer, muscle, nerves, and blood vessels.

Some animals did develop strictures - narrowing of the graft - but these were managed through endoscopy, mirroring the routine clinical practice used for similar complications in human patients.

Why the oesophagus is uniquely difficult

The oesophagus presents engineering challenges that other organs do not. It has no dedicated blood supply from its own vessels, which means it cannot be transplanted the way a kidney or liver can. It must perform coordinated muscular contractions. It must resist acid reflux from below. And in a child, it must grow.

Previous tissue engineering efforts have demonstrated individual pieces of this puzzle - decellularized scaffolds, cell seeding, bioreactor maturation - but this is the first time the full process has been completed in a large animal model with the outcome being a functional, growing organ that does not need immunosuppression.

"The oesophagus is a really complex organ," said Professor Paolo De Coppi, who led the research team at UCL Great Ormond Street Institute of Child Health. "To develop alternatives, it is essential to work with animal models that closely reflect human anatomy and function. In this respect, the pig oesophagus closely resembles the human one."

The path from pig model to paediatric clinic

If the technology translates to humans, the workflow would look remarkably similar to what the researchers already demonstrated. Different sizes of pig-derived scaffolds could be stored in advance, ready to be personalized whenever a child needs one. The muscle cells for seeding would come from a biopsy taken during the same surgery that places the initial feeding tube - no extra procedure needed. The resulting graft would contain the child's own cells, grow with them over time, and require no long-term immunosuppressive drugs.

Dr. Marco Pellegrini, a senior researcher on the study, described the practical implications: the approach would allow clinicians to build a child a new oesophagus using cells collected during a surgery they are already having, combined with a pre-prepared scaffold from pig tissue.

The team estimates that first-in-human trials could begin within five years. Before that happens, they need to refine the process to generate longer grafts, standardize manufacturing, reduce manual steps, and complete further safety testing. Studies will also focus on tracking cell behavior over time and optimizing blood flow to the graft.

Pig tissue as platform, not just precedent

De Coppi drew a parallel to cardiac surgery, where pig heart valves have been used to save lives for more than 50 years. That technology is now routine. More recently, xenotransplantation - transplanting whole organs from pigs to humans - has been explored as a response to organ shortages. The approach used in this study sits between those two poles: it uses pig tissue as a starting platform, but strips away everything biological from the donor, replacing it with the patient's own cells.

"We demonstrate that pig tissue, once stripped of all cellular material, can serve as a scaffold to engineer humanised tissue that is fully biocompatible," De Coppi said.

What remains uncertain

This is a pig study, not a human trial. The eight-animal cohort is small by clinical standards, and six months of follow-up, while encouraging, does not tell us about years-long outcomes. Stricture formation, while manageable, occurred frequently enough to warrant attention in any human application. The long-term durability of the engineered tissue, its response to acid exposure over years, and its behavior during periods of rapid childhood growth all remain open questions.

Manufacturing consistency is another challenge. Moving from a research lab producing individual grafts to a standardized process capable of serving a clinical population will require significant engineering work. Regulatory approval for a therapy that combines animal-derived scaffolds with patient-derived cells will involve navigating complex frameworks across multiple jurisdictions.

Still, for families like Casey's, the prospect of a single early operation that delivers a functioning, growing food pipe - rather than the current cycle of major surgeries and their cascading complications - represents something worth waiting for.